RU2007139915A - Haemophilus influenzae типа в - Google Patents
Haemophilus influenzae типа в Download PDFInfo
- Publication number
- RU2007139915A RU2007139915A RU2007139915/13A RU2007139915A RU2007139915A RU 2007139915 A RU2007139915 A RU 2007139915A RU 2007139915/13 A RU2007139915/13 A RU 2007139915/13A RU 2007139915 A RU2007139915 A RU 2007139915A RU 2007139915 A RU2007139915 A RU 2007139915A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- polypeptide
- seq
- antibody
- composition
- Prior art date
Links
- 241000606768 Haemophilus influenzae Species 0.000 title claims 2
- 229940045808 haemophilus influenzae type b Drugs 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 claims abstract 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract 17
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 17
- 229920001184 polypeptide Polymers 0.000 claims abstract 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 239000012634 fragment Substances 0.000 claims abstract 6
- 239000002773 nucleotide Substances 0.000 claims abstract 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 239000012646 vaccine adjuvant Substances 0.000 claims abstract 2
- 229940124931 vaccine adjuvant Drugs 0.000 claims abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Materials For Photolithography (AREA)
- Developing Agents For Electrophotography (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66792105P | 2005-03-30 | 2005-03-30 | |
| US60/667,921 | 2005-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007139915A true RU2007139915A (ru) | 2009-05-10 |
Family
ID=37087506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007139915/13A RU2007139915A (ru) | 2005-03-30 | 2006-03-30 | Haemophilus influenzae типа в |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20100034822A1 (enExample) |
| EP (1) | EP1871888A4 (enExample) |
| JP (1) | JP2008538183A (enExample) |
| CN (1) | CN101687025A (enExample) |
| AU (1) | AU2006235045A1 (enExample) |
| BR (1) | BRPI0609460A2 (enExample) |
| CA (1) | CA2602665A1 (enExample) |
| MX (1) | MX2007012057A (enExample) |
| NZ (2) | NZ591415A (enExample) |
| RU (1) | RU2007139915A (enExample) |
| WO (1) | WO2006110413A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| HUE061068T2 (hu) | 2010-08-31 | 2023-05-28 | Glaxosmithkline Biologicals Sa | Pegilált liposzómák immunogént kódoló RNS szállítására |
| EP4098324A1 (en) | 2010-10-11 | 2022-12-07 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| JP2014516028A (ja) * | 2011-05-11 | 2014-07-07 | リースベック ヘルスケア スウェーデン アクティエボラーグ | ラミニン及びビトロネクチン結合特性を有するタンパク質ｆ−新規インフルエンザ菌付着因子 |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| EP2750707B1 (en) | 2011-08-31 | 2018-10-24 | GlaxoSmithKline Biologicals SA | Pegylated liposomes for delivery of immunogen-encoding rna |
| CA2882382A1 (en) | 2012-09-18 | 2014-03-27 | Novartis Ag | Outer membrane vesicles |
| WO2014136086A1 (en) | 2013-03-08 | 2014-09-12 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| AR090303A1 (es) * | 2013-03-11 | 2014-11-05 | Consejo Nac Invest Cient Tec | Polipeptido mutado, cepa de bacterias que lo comprende y metodos para detectar diferentes cationes metalicos simultaneamente |
| RU2015155601A (ru) | 2013-06-10 | 2017-07-14 | Мерк Шарп И Доум Корп. | Нейтрализующие цитомегаловирус (цмв) антигенсвязывающие белки |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| US10125092B2 (en) | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201508860D0 (en) | 2015-05-22 | 2015-07-01 | Nat Univ Ireland | Diagnostic method |
| US11401520B2 (en) | 2016-10-21 | 2022-08-02 | The Research Foundation For The State University Of New York | Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US20220143168A1 (en) * | 2019-02-27 | 2022-05-12 | Evaxion Biotech A/S | Vaccines targeting H. influenzae |
| CN114126715A (zh) * | 2019-05-31 | 2022-03-01 | 罗根生物技术有限公司 | 组合物以及解除细菌内毒素毒性的方法 |
| US11357845B2 (en) * | 2019-07-08 | 2022-06-14 | The Trustees Of The University Of Pennsylvania | Protein antigens for vaccinating against nontypeable Haemophilus influenzae |
| WO2022081750A1 (en) | 2020-10-14 | 2022-04-21 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| CA3191332A1 (en) * | 2020-10-30 | 2022-05-05 | Gen-Probe Incorporated | Compositions and methods for detecting influenza a, influenza b, and sars-cov-2 |
| WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355450B1 (en) * | 1995-04-21 | 2002-03-12 | Human Genome Sciences, Inc. | Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof |
| GB9513074D0 (en) * | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
| US6593114B1 (en) * | 1996-01-05 | 2003-07-15 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| US6914131B1 (en) * | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| US6730827B1 (en) * | 1998-07-14 | 2004-05-04 | E. I. Du Pont De Nemours And Company | Genes encoding plant adenosine 5′-phosphosulfate reductase |
| US7365185B2 (en) * | 2000-07-19 | 2008-04-29 | Monsanto Technology Llc | Genomic plant sequences and uses thereof |
| US20020061569A1 (en) * | 2000-03-21 | 2002-05-23 | Robert Haselbeck | Identification of essential genes in prokaryotes |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| WO2006138527A2 (en) * | 2005-06-16 | 2006-12-28 | Children's Hospital, Inc. | Genes of an otitis media isolate of nontypeable haemophilus influenzae |
| EP2330117A1 (en) * | 2003-03-06 | 2011-06-08 | Nationwide Children's Hospital, Inc. | Genes of an otitis media isolate of nontypeable Haemophilus influenzae |
| GB0315022D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Virulence-associated adhesins |
| GB0410866D0 (en) * | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
-
2006
- 2006-03-30 BR BRPI0609460-0A patent/BRPI0609460A2/pt not_active IP Right Cessation
- 2006-03-30 WO PCT/US2006/012606 patent/WO2006110413A2/en not_active Ceased
- 2006-03-30 CA CA002602665A patent/CA2602665A1/en not_active Abandoned
- 2006-03-30 MX MX2007012057A patent/MX2007012057A/es unknown
- 2006-03-30 US US11/887,712 patent/US20100034822A1/en not_active Abandoned
- 2006-03-30 RU RU2007139915/13A patent/RU2007139915A/ru not_active Application Discontinuation
- 2006-03-30 NZ NZ591415A patent/NZ591415A/xx not_active IP Right Cessation
- 2006-03-30 NZ NZ562381A patent/NZ562381A/en not_active IP Right Cessation
- 2006-03-30 EP EP06758272.6A patent/EP1871888A4/en not_active Withdrawn
- 2006-03-30 AU AU2006235045A patent/AU2006235045A1/en not_active Abandoned
- 2006-03-30 CN CN200680018203A patent/CN101687025A/zh active Pending
- 2006-03-30 JP JP2008504533A patent/JP2008538183A/ja active Pending
-
2011
- 2011-12-21 US US13/333,815 patent/US20120093868A1/en not_active Abandoned
-
2014
- 2014-06-19 US US14/309,829 patent/US20140302078A1/en not_active Abandoned
-
2015
- 2015-10-06 US US14/876,623 patent/US20160024157A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101687025A (zh) | 2010-03-31 |
| US20120093868A1 (en) | 2012-04-19 |
| EP1871888A4 (en) | 2013-08-21 |
| WO2006110413A2 (en) | 2006-10-19 |
| US20100034822A1 (en) | 2010-02-11 |
| NZ562381A (en) | 2011-06-30 |
| AU2006235045A1 (en) | 2006-10-19 |
| BRPI0609460A2 (pt) | 2010-04-13 |
| EP1871888A2 (en) | 2008-01-02 |
| CA2602665A1 (en) | 2006-10-19 |
| US20160024157A1 (en) | 2016-01-28 |
| NZ591415A (en) | 2012-10-26 |
| MX2007012057A (es) | 2007-11-23 |
| US20140302078A1 (en) | 2014-10-09 |
| JP2008538183A (ja) | 2008-10-16 |
| WO2006110413A9 (en) | 2010-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007139915A (ru) | Haemophilus influenzae типа в | |
| RU2009102815A (ru) | Полипептиды из neisseria meningitidis | |
| RU2006144093A (ru) | Полипептиды нетипируемой haemophilus influenzae | |
| JP2008538183A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2003527079A5 (enExample) | ||
| JP2005511076A5 (enExample) | ||
| JP2008508859A5 (enExample) | ||
| MXPA05011110A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. | |
| JP2010166916A5 (enExample) | ||
| JP2010512792A5 (enExample) | ||
| RU2012139432A (ru) | Полипептиды | |
| RU2002117308A (ru) | 85 кДа АНТИГЕН NEISSERIA | |
| JP6505110B2 (ja) | ＯｓｐＡの突然変異体断片、並びにそれに関する方法および使用 | |
| RU2004121149A (ru) | Иммунизация против chlamydia trachomatis | |
| JP2008529558A5 (enExample) | ||
| WO2003063766A3 (en) | Novel immunogenic compositions for the prevention and treatment of meningococcal disease | |
| JP2023015301A5 (enExample) | ||
| EP2292648A3 (en) | Small Streptococcus pyogenes antigens and their use | |
| JP2013523718A5 (enExample) | ||
| RU2010130338A (ru) | Мутантные формы стрептолизина о | |
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| ES2551699T3 (es) | Composiciones, procedimientos y kits | |
| RU2014138418A (ru) | Белки пилей и композиции | |
| RU2008137968A (ru) | Иммуномодулирующие и противоопухолевые пептиды |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20120111 |